An alternate pathophysiologic paradigm of sepsis and septic shock: Implications for optimizing antimicrobial therapy

Virulence

Volumn 5, Issue 1, 2014, Pages 80-97

  Kumar, Anand ^a  

^a HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antibiotic; Antimicrobial; Combination therapy; Infection; Life threatening infection; Pharmacokinetics; Sepsis; Septic shock; Survival

Indexed keywords

AMINOGLYCOSIDE; ANIDULAFUNGIN; AZTREONAM; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BETA LACTAM; CASPOFUNGIN; CEFMENOXIME; CEFTAZIDIME; CHLORAMPHENICOL; COLISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUCONAZOLE; GENTAMICIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE; LINEZOLID; PENICILLIN DERIVATIVE; PROSTAGLANDIN E2; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE; THROMBOXANE; TIGECYCLINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIMICROBIAL THERAPY; AUTOPSY; BACTEREMIA; BACTERIAL CLEARANCE; BACTERIAL PERITONITIS; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; HUMAN; HYPOTENSION; MENINGOCOCCEMIA; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; PATHOPHYSIOLOGY; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VENTILATOR ASSOCIATED PNEUMONIA;

ANTIBIOTIC; ANTIMICROBIAL; COMBINATION THERAPY; INFECTION; LIFE-THREATENING INFECTION; PHARMACOKINETICS; SEPSIS; SEPTIC SHOCK; SURVIVAL;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; HUMANS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84891650309     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.26913     Document Type: Review

References (264)

1. Finland M, Jones WF, Barnes MW. Occurence of serious bacterial infections since the introduction of antibacterial agents. JAMA 1959; 84:2188-97; http://dx.doi.org/10.1001/jama.1959.63010180008012.
2. Hemminki E, Paakkulainen A. The effect of antibiotics on mortality from infectious diseases in Sweden and Finland. Am J Public Health 1976; 66:1180-4. PMID:1008114; http://dx.doi.org/10.2105/AJPH.66.12.1180.
3. Kreger BE, Craven DE, McCabe WR. Gramnegative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68:344-55. PMID:6987871; http://dx.doi.org/10.1016/0002-9343(80)90102-3.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54. PMID:12700374; http://dx.doi.org/10.1056/NEJMoa022139.
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10. PMID:11445675; http://dx.doi.org/10.1097/00003246-200107000-00002.
6. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, et al.; Academic Medical Center Consortium Sepsis Project Working Group. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278:234-40. PMID:9218672; http://dx.doi.org/10.1001/jama.1997.03550030074038.
7. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Régnier B; French ICU Group for Severe Sepsis. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 1995; 274:968-74. PMID:7674528; http://dx.doi.org/10.1001/jama.1995.03530120060042.
8. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B; CUB-Réa Network. Current epidemiology of septic shock: the CUB-Réa Network. Am J Respir Crit Care Med 2003; 168:165-72. PMID:12851245; http://dx.doi.org/10.1164/rccm.2201087.
9. Pakhale S, Roberts D, Light B, Sharma S, Kumar A. A geographically and temporally comprehensive analysis of septic shock: Impact of age, sex and socioeconomic status. Crit Care Med 2005; 33:103-M.
10. Eichacker PQ, Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007; 33:396-9. PMID:17325833; http://dx.doi.org/10.1007/s00134-007-0556-8.
11. Gårdlund B. Activated protein C (Xigris) treatment in sepsis: a drug in trouble. Acta Anaesthesiol Scand 2006; 50:907-10. PMID:16923083; http://dx.doi.org/10.1111/j.1399-6576.2006.01086.x
12. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, et al.; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-64. PMID:22616830; http://dx.doi.org/10.1056/NEJMoa1202290.
13. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ; The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55. PMID:1303622; http://dx.doi.org/10.1378/chest.101.6.1644.
14. van der Poll T, van Deventer SJ. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999; 13:413-26, ix. PMID:10340175; http://dx.doi.org/10.1016/S0891-5520(05)70083-0.
15. van der Poll T. Coagulation and inflammation. J Endotoxin Res 2001; 7:301-4. PMID:11717589; http://dx.doi.org/10.1177/09680519010070040301.
16. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50. PMID:12519925; http://dx.doi.org/10.1056/NEJMra021333.
17. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007; 170:1435-44. PMID:17456750; http://dx.doi.org/10.2353/ajpath.2007.060872.
18. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, Yeh T, Kim SS, Cafaro DP, Scannon PJ, et al. Recombinant bactericidal/permeabilityincreasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000; 356:961-7. PMID:11041396; http://dx.doi.org/10.1016/S0140-6736(00)02712-4.
19. Freeman BD, Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 2000; 9:1651-63. PMID:11060768; http://dx.doi.org/10.1517/13543784.9.7.1651.
20. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709. PMID:11236773; http://dx.doi.org/10.1056/NEJM200103083441001.
21. Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, Gulati H, Kumar A. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36:2973-9. PMID:18824906; http://dx.doi.org/10.1097/CCM.0b013e31818b8c6b
22. Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A, Shamse Tabriz M, Sharma M, Saeed S. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006; 38:7-14. PMID:16338832; http://dx.doi.org/10.1080/00365540500372846.
23. Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007; 167:1861-7. PMID:17893307; http://dx.doi.org/10.1001/archinte.167.17.1861.
24. Chowers MY, Gottesman B, Paul M, Weinberger M, Pitlik S, Leibovici L. Persistent bacteremia in the absence of defined intravascular foci: clinical significance and risk factors. Eur J Clin Microbiol Infect Dis 2003; 22:592-6. PMID:14513406; http://dx.doi.org/10.1007/s10096-003-0999-y
25. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366:1435-42. PMID:16243088; http://dx.doi.org/10.1016/S0140-6736(05)67490-9.
26. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, et al.; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-82. PMID:17568028; http://dx.doi.org/10.1056/NEJMoa066906.
27. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-80. PMID:1929035; http://dx.doi.org/10.7326/0003-4819-115-9-674.
28. Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR, Dünser MW. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 2009; 108:1841-7. PMID:19448210; http://dx.doi.org/10.1213/ane.0b013e318195e11d
29. Wiggers CJ. Experimental Haemorrhage Shoc k. Physiology of Shock: The Commonwealth Fund New York, NY: Harvard University Press, 1950:121-43.
30. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109:1223-5. PMID:15007008; http://dx.doi.org/10.1161/01.CIR.0000121424.76486.20.
31. Simoons ML, Serruys PW, vd Brand M, Bär F, de Zwaan C, Res J, Verheugt FW, Krauss XH, Remme WJ, Vermeer F, et al. Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The Netherlands. Lancet 1985; 2:578-82. PMID:2863596; http://dx.doi.org/10.1016/S0140-6736(85)90584-7.
32. Wood KE. The presence of shock defines the threshold to initiate thrombolytic therapy in patients with pulmonary embolism. Intensive Care Med 2002; 28:1537-46. PMID:12583371; http://dx.doi.org/10.1007/s00134-002-1486-0.
33. Sampalis JS, Lavoie A, Williams JI, Mulder DS, Kalina M. Impact of on-site care, prehospital time, and level of in-hospital care on survival in severely injured patients. J Trauma 1993; 34:252-61. PMID:8459466; http://dx.doi.org/10.1097/00005373-199302000-00014.
34. Vallés J, Rello J, Ochagavía A, Garnacho J, Alcalá MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123:1615-24. PMID:12740282; http://dx.doi.org/10.1378/chest.123.5.1615.
35. Ulloa L, Tracey KJ. The "cytokine profile": a code for sepsis. Trends Mol Med 2005; 11:56-63. PMID:15694867; http://dx.doi.org/10.1016/j.molmed.2004.12.007.
36. Wang H, Czura CJ, Tracey KJ. Lipid unites disparate syndromes of sepsis. Nat Med 2004; 10:124-5. PMID:14760415; http://dx.doi.org/10.1038/nm0204-124.
37. Simon PM, Delude RL, Lee M, Kong L, Guzik LJ, Huang DT, Angus DC, Kellum JA; GenIMS Investigators. Duration and magnitude of hypotension and monocyte deactivation in patients with community-acquired pneumonia. Shock 2011; 36:553-9. PMID:22080961; http://dx.doi.org/10.1097/SHK.0b013e318235331e
38. Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, Taiberg L, Osman J, Trenholme G, Opal SM, Goldfarb R, et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006; 193:251-8. PMID:16362889; http://dx.doi.org/10.1086/498909.
39. Øvstebø R, Brandtzaeg P, Brusletto B, Haug KB, Lande K, Høiby EA, Kierulf P. Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol 2004; 42:2980-7. PMID:15243048; http://dx.doi.org/10.1128/JCM.42.7.2980-2987.2004.
40. Lala HM, Mills GD, Barratt K, Bonning J, Manikkam NE, Martin D. Meningococcal disease deaths and the frequency of antibiotic administration delays. J Infect 2007; 54:551-7. PMID:17147958; http://dx.doi.org/10.1016/j.jinf.2006.10.050.
41. Yagupsky P, Nolte FS. Quantitative aspects of septicemia. Clin Microbiol Rev 1990; 3:269-79. PMID:2200606.
42. Rello J, Lisboa T, Lujan M, Gallego M, Kee C, Kay I, Lopez D, Waterer GW; DNA-Neumococo Study Group. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009; 136:832-40. PMID:19433527; http://dx.doi.org/10.1378/chest.09-0258.
43. Kreger BE, Craven DE, Carling PC, McCabe WR. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68:332-43. PMID:6987870; http://dx.doi.org/10.1016/0002-9343(80)90101-1.
44. DuPont HL, Spink WW. Infections due to gramnegative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958-1966. Medicine (Baltimore) 1969; 48:307-32. PMID:4897133; http://dx.doi.org/10.1097/00005792-196907000-00003.
45. Marra AR, Edmond MB, Forbes BA, Wenzel RP, Bearman GML. Time to blood culture positivity as a predictor of clinical outcome of Staphylococcus aureus bloodstream infection. J Clin Microbiol 2006; 44:1342-6. PMID:16597860; http://dx.doi.org/10.1128/JCM.44.4.1342-1346.2006.
46. Khatib R, Riederer K, Saeed S, Johnson LB, Fakih MG, Sharma M, Tabriz MS, Khosrovaneh A. Time to positivity in Staphylococcus aureus bacteremia: possible correlation with the source and outcome of infection. Clin Infect Dis 2005; 41:594-8. PMID:16080079; http://dx.doi.org/10.1086/432472.
47. Liao CH, Lai CC, Hsu MS, Huang YT, Chu FY, Hsu HS, Hsueh PR. Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective cohort study. Clin Microbiol Infect 2009; 15:1119-25. PMID:19392886; http://dx.doi.org/10.1111/j.1469-0691.2009.02720.x
48. Peralta G, Roiz MP, Sánchez MB, Garrido JC, Ceballos B, Rodríguez-Lera MJ, Mateos F, De Benito I. Time-to-positivity in patients with Escherichia coli bacteraemia. Clin Microbiol Infect 2007; 13:1077-82. PMID:17727685; http://dx.doi.org/10.1111/j.1469-0691.2007.01817.x
49. Martínez JA, Soto S, Fabrega A, Almela M, Mensa J, Soriano A, Marco F, Jimenez de Anta MT, Vila J. Relationship of phylogenetic background, biofilm production, and time to detection of growth in blood culture vials with clinical variables and prognosis associated with Escherichia coli bacteremia. J Clin Microbiol 2006; 44:1468-74. PMID:16597878; http://dx.doi.org/10.1128/JCM.44.4.1468-1474.2006.
50. Chuang YC, Chang SC, Wang WK. Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia. Crit Care Med 2012; 40:2273-80. PMID:22809902; http://dx.doi.org/10.1097/CCM.0b013e3182515190.
51. Chandrasekar PH, Crane LR, Bailey EJ. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J Antimicrob Chemother 1987; 19:321-9. PMID:3106305; http://dx.doi.org/10.1093/jac/19.3.321.
52. Ehrlich P. Address in Pathology, ON CHEMIOTHERAPY: Delivered before the Seventeenth International Congress of Medicine. Br Med J 1913; 2:353-9. PMID:20766753; http://dx.doi.org/10.1136/bmj.2.2746.353.
53. Ammerlaan H, Seifert H, Harbarth S, Brun-Buisson C, Torres A, Antonelli M, Kluytmans J, Bonten M; European Practices of Infections with Staphylococcus aureus (SEPIA) Study Group. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 2009; 49:997-1005. PMID:19719417; http://dx.doi.org/10.1086/605555.
54. Haddy RI, Nadkarni DD, Mann BL, Little DR, Domers TD, Clover RD, Silvers MJ. Clostridial bacteremia in the community hospital. Scand J Infect Dis 2000; 32:27-30. PMID:10716073; http://dx.doi.org/10.1080/00365540050164173.
55. Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with communityacquired bacteraemia due to urinary tract infection. J Infect 1997; 35:283-8. PMID:9459403; http://dx.doi.org/10.1016/S0163-4453(97)93194-7.
56. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002; 34:1600-6. PMID:12032895; http://dx.doi.org/10.1086/340616.
57. Blot S, Depuydt P, Vogelaers D, Decruyenaere J, De Waele J, Hoste E, Peleman R, Claeys G, Verschraegen G, Colardyn F, et al. Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. Infect Control Hosp Epidemiol 2005; 26:575-9. PMID:16018434; http://dx.doi.org/10.1086/502575.
58. Young LS, Martin WJ, Meyer RD, Weinstein RJ, Anderson ET. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med 1977; 86:456-71. PMID:403841; http://dx.doi.org/10.7326/0003-4819-86-4-456.
59. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995; 21:1417-23. PMID:8749626; http://dx.doi.org/10.1093/clinids/21.6.1417.
60. Nguyen MH, Peacock JE Jr., Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429-35. PMID:7503601; http://dx.doi.org/10.1001/archinte.1995.00430220087009.
61. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, Wagener MM, Schmitt B, Muder RR. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135:484-92. PMID:11578151; http://dx.doi.org/10.7326/0003-4819-135-7-200110020-00007.
62. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, et al.; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237-48. PMID:19696123; http://dx.doi.org/10.1378/chest.09-0087.
63. Garnacho-Montero J, García-Cabrera E, Diaz-Martín A, Lepe-Jiménez JA, Iraurgi-Arcarazo P, Jiménez-Alvarez R, Revuelto-Rey J, Aznar-Martín J. Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment. Scand J Infect Dis 2010; 42:185-92. PMID:20085422; http://dx.doi.org/10.3109/00365540903418522.
64. Lueangarun S, Leelarasamee A. Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: A retrospective study. Interdiscip Perspect Infect Dis 2012; 2012:765205. PMID:22919379; http://dx.doi.org/10.1155/2012/765205.
65. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, Kollef MH. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010; 54:1742-8. PMID:20160050; http://dx.doi.org/10.1128/AAC.01365-09.
66. McGregor JC, Rich SE, Harris AD, Perencevich EN, Osih R, Lodise TP Jr., Miller RR, Furuno JP. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007; 45:329-37. PMID:17599310; http://dx.doi.org/10.1086/519283.
67. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008; 47(Suppl 1):S3-13. PMID:18713047; http://dx.doi.org/10.1086/590061.
68. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54:4851-63. PMID:20733044; http://dx.doi.org/10.1128/AAC.00627-10.
69. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74. PMID:10027448; http://dx.doi.org/10.1378/chest.115.2.462.
70. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55. PMID:10893372; http://dx.doi.org/10.1378/chest.118.1.146.
71. Kaufman D, Haas CE, Edinger R, Hollick G. Antibiotic susceptibility in the surgical intensive care unit compared with the hospital-wide antibiogram. Arch Surg 1998; 133:1041-5. PMID:9790198; http://dx.doi.org/10.1001/archsurg.133.10.1041.
72. Green DL. Selection of an empiric antibiotic regimen for hospital-acquired pneumonia using a unit and culture-type specific antibiogram. J Intensive Care Med 2005; 20:296-301. PMID:16145220; http://dx.doi.org/10.1177/0885066605278650.
73. Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, Thys JP. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60-6, discussion 67-8. PMID:10433566; http://dx.doi.org/10.1086/520182.
74. Raineri E, Pan A, Mondello P, Acquarolo A, Candiani A, Crema L. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am J Infect Control 2008; 36:283-90. PMID:18455049; http://dx.doi.org/10.1016/j.ajic.2007.06.009.
75. Kerremans JJ, Verbrugh HA, Vos MC. Frequency of microbiologically correct antibiotic therapy increased by infectious disease consultations and microbiological results. J Clin Microbiol 2012; 50:2066-8. PMID:22422850; http://dx.doi.org/10.1128/JCM.06051-11.
76. Fowler VG Jr., Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, Gottlieb G, McClelland RS, Corey GR. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27:478-86. PMID:9770144; http://dx.doi.org/10.1086/514686.
77. Kollef MH, Morrow LE, Niederman MS, Leeper KV, Anzueto A, Benz-Scott L, Rodino FJ. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210-8. PMID:16685011; http://dx.doi.org/10.1378/chest.129.5.1210.
78. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-11. PMID:10934078; http://dx.doi.org/10.1164/ajrccm.162.2.9909095.
79. Aarts MAW, Brun-Buisson C, Cook DJ, Kumar A, Opal S, Rocker G, Smith T, Vincent JL, Marshall JC. Antibiotic management of suspected nosocomial ICU-acquired infection: does prolonged empiric therapy improve outcome? Intensive Care Med 2007; 33:1369-78. PMID:17558493; http://dx.doi.org/10.1007/s00134-007-0723-y
80. Joung MK, Lee JA, Moon SY, Cheong HS, Joo EJ, Ha YE, Sohn KM, Chung SM, Suh GY, Chung DR, et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care 2011; 15:R79. PMID:21366903; http://dx.doi.org/10.1186/cc10072.
81. Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 2008; 52:3188-94. PMID:18625778; http://dx.doi.org/10.1128/AAC.01553-07.
82. Fang CT, Shau WY, Hsueh PR, Chen YC, Wang JT, Hung CC, Huang LY, Chang SC. Early empirical glycopeptide therapy for patients with methicillinresistant Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob Chemother 2006; 57:511-9. PMID:16443700; http://dx.doi.org/10.1093/jac/dkl006.
83. Giner AM, Kuster SP, Zbinden R, Ruef C, Ledergerber B, Weber R. Initial management of and outcome in patients with pneumococcal bacteremia: a retrospective study at a Swiss university hospital, 2003-2009. Infection 2011; 39:519-26. PMID:22065426; http://dx.doi.org/10.1007/s15010-011-0218-1.
84. Corona A, Bertolini G, Lipman J, Wilson AP, Singer M. Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010; 65:1276-85. PMID:20335186; http://dx.doi.org/10.1093/jac/dkq088.
85. Silber SH, Garrett C, Singh R, Sweeney A, Rosenberg C, Parachiv D, Okafo T. Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe communityacquired pneumonia. Chest 2003; 124:1798-804. PMID:14605051; http://dx.doi.org/10.1378/chest.124.5.1798.
86. Dedier J, Singer DE, Chang Y, Moore M, Atlas SJ. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med 2001; 161:2099-104. PMID:11570938; http://dx.doi.org/10.1001/archinte.161.17.2099.
87. Cheng AC, Buising KL. Delayed administration of antibiotics and mortality in patients with communityacquired pneumonia. Ann Emerg Med 2009; 53:618-24. PMID:18723255; http://dx.doi.org/10.1016/j. annemergmed.2008.07.017.
88. Kaasch AJ, Rieg S, Kuetscher J, Brodt HR, Widmann T, Herrmann M, Meyer C, Welte T, Kern P, Haars U, et al.; preSABATO study group*. Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study. Infection 2013; 41:979-85. PMID:23539143; http://dx.doi.org/10.1007/s15010-013-0428-9.
89. Anderson DJ, Engemann JJ, Harrell LJ, Carmeli Y, Reller LB, Kaye KS. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2006; 50:1715-20. PMID:16641440; http://dx.doi.org/10.1128/AAC.50.5.1715-1720.2006.
90. Whitelaw DA, Rayner BL, Willcox PA. Communityacquired bacteremia in the elderly: a prospective study of 121 cases. J Am Geriatr Soc 1992; 40:996-1000. PMID:1401689.
91. Erbay A, Idil A, Gözel MG, Mumcuoǧlu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009; 34:575-9. PMID:19740628; http://dx.doi.org/10.1016/j.ijantimicag.2009.07.006.
92. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25:181-5. PMID:16505987; http://dx.doi.org/10.1007/s10096-006-0096-0.
93. Lodise TP Jr., Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51:3510-5. PMID:17646415; http://dx.doi.org/10.1128/AAC.00338-07.
94. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-23. PMID:12766837; http://dx.doi.org/10.1086/375057.
95. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745-51. PMID:12955633; http://dx.doi.org/10.1086/377200.
96. Menéndez R, Torres A, Reyes S, Zalacain R, Capelastegui A, Aspa J, Borderías L, Martín-Villasclaras JJ, Bello S, Alfageme I, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012; 39:156-62. PMID:21828033; http://dx.doi.org/10.1183/09031936.00188710.
97. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278:2080-4. PMID:9403422; http://dx.doi.org/10.1001/jama.1997.03550230056037.
98. Mathevon T, Souweine B, Traoré O, Aublet B, Caillaud D. ICU-acquired nosocomial infection: impact of delay of adequate antibiotic treatment. Scand J Infect Dis 2002; 34:831-5. PMID:12578154; http://dx.doi.org/10.1080/0036554021000026934.
99. Heath CH, Grove DI, Looke DFM. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996; 15:286-90. PMID:8781878; http://dx.doi.org/10.1007/BF01695659.
100. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilatorassociated pneumonia. Chest 2002; 122:262-8. PMID:12114368; http://dx.doi.org/10.1378/chest.122.1.262.
101. Gacouin A, Le Tulzo Y, Lavoue S, Camus C, Hoff J, Bassen R, Arvieux C, Heurtin C, Thomas R. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med 2002; 28:686-91. PMID:12107671; http://dx.doi.org/10.1007/s00134-002-1304-8.
102. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637-44. PMID:15037492; http://dx.doi.org/10.1001/archinte.164.6.637.
103. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31. PMID:16758414; http://dx.doi.org/10.1086/504810.
104. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5. PMID:16127033; http://dx.doi.org/10.1128/AAC.49.9.3640-3645.2005.
105. Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in nonimmunocompromised adult patients. J Antimicrob Chemother 2010; 65:1765-70. PMID:20554567; http://dx.doi.org/10.1093/jac/dkq216.
106. Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther 2009; 16:508-11. PMID:19531934; http://dx.doi.org/10.1097/MJT.0b013e3181a1afb7.
107. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54:184-90. PMID:19884371; http://dx.doi.org/10.1128/AAC.00945-09.
108. Zahar JR, Azoulay E, Klement E, De Lassence A, Lucet JC, Regnier B, Schlemmer B, Bedos JP. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med 2001; 27:513-20. PMID:11355119; http://dx.doi.org/10.1007/s001340000849.
109. Kethireddy S, Light RB, Miranejad Y, Maki D, Arabi Y, Lapinsky S, Simon D, Kumar A, Parrillo JE, Kumar A. Mycobacterium tuberculosis Septic Shock. Chest 2013; 144:474-82. PMID:23429859; http://dx.doi.org/10.1378/chest.12-1286/
110. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS, Goyal M. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045-53. PMID:20048677; http://dx.doi.org/10.1097/CCM.0b013e3181cc4824.
111. Barie PS, Hydo LJ, Shou J, Larone DH, Eachempati SR. Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt) 2005; 6:41-54. PMID:15865550; http://dx.doi.org/10.1089/sur.2005.6.41.
112. Jamieson WG, Pliagus G, Marchuk S, DeRose G, Moffat D, Stafford L, Finley RJ, Sibbald W, Taylor BM, Duff J. Effect of antibiotic and fluid resuscitation upon survival time in experimental intestinal ischemia. Surg Gynecol Obstet 1988; 167:103-8. PMID:3400026.
113. Greisman SE, DuBuy JB, Woodward CL. Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone. Infect Immun 1979; 25:538-57. PMID:385500.
114. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621-9. PMID:3927867; http://dx.doi.org/10.1001/archinte.1985.00360090089015.
115. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96. PMID:16625125; http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9.
116. Natsch S, Kullberg BJ, van der Meer JW, Meis JF. Delay in administering the first dose of antibiotics in patients admitted to hospital with serious infections. Eur J Clin Microbiol Infect Dis 1998; 17:681-4. PMID:9865979; http://dx.doi.org/10.1007/s100960050160.
117. Proulx N, Fréchette D, Toye B, Chan J, Kravcik S. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 2005; 98:291-8. PMID:15760921; http://dx.doi.org/10.1093/qjmed/hci047.
118. van Tuijn CF, Luitse JS, van der Valk M, van Wissen S, Prins M, Rosmulder R, Geerlings SE. Reduction of the door-to-needle time for administration of antibiotics in patients with a severe infection: a tailored intervention project. Quicker, faster, better? Neth J Med 2010; 68:123-7. PMID:20308707.
119. Clarke RT, Warnick J, Stretton K, Littlewood TJ. Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit. Br J Haematol 2011; 153:773-9. PMID:21517822; http://dx.doi.org/10.1111/j.1365-2141.2011.08693.x
120. Aronin SI, Peduzzi P, Quagliarello VJ. Communityacquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129:862-9. PMID:9867727; http://dx.doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00004.
121. Miner JR, Heegaard W, Mapes A, Biros M. Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. J Emerg Med 2001; 21:387-92. PMID:11728765; http://dx.doi.org/10.1016/S0736-4679(01)00407-3.
122. Larché J, Azoulay E, Fieux F, Mesnard L, Moreau D, Thiery G, Darmon M, Le Gall JR, Schlemmer B. Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 2003; 29:1688-95. PMID:13680115; http://dx.doi.org/10.1007/s00134-003-1957-y
123. Hamandi B, Holbrook AM, Humar A, Brunton J, Papadimitropoulos EA, Wong GG, Thabane L. Delay of adequate empiric antibiotic therapy is associated with increased mortality among solid-organ transplant patients. Am J Transplant 2009; 9:1657-65. PMID:19459798; http://dx.doi.org/10.1111/j.1600-6143.2009.02664.x
124. Gurnani PK, Patel GP, Crank CW, Vais D, Lateef O, Akimov S, Balk R, Simon D. Impact of the implementation of a sepsis protocol for the management of fluid-refractory septic shock: A single-center, before-and-after study. Clin Ther 2010; 32:1285-93. PMID:20678676; http://dx.doi.org/10.1016/j.clinthera.2010.07.003.
125. Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, Clark NM. Timing of susceptibilitybased antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 2012; 67:707-14. PMID:22184469; http://dx.doi.org/10.1093/jac/dkr511.
126. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Pérez XL, Sirvent JM; Edusepsis Study Group. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180:861-6. PMID:19696442; http://dx.doi.org/10.1164/rccm.200812-1912OC
127. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327. PMID:18158437; http://dx.doi.org/10.1097/01.CCM.0000298158.12101.41.
128. Varpula M, Karlsson S, Parviainen I, Ruokonen E, Pettilä V; Finnsepsis Study Group. Communityacquired septic shock: early management and outcome in a nationwide study in Finland. Acta Anaesthesiol Scand 2007; 51:1320-6. PMID:17944634; http://dx.doi.org/10.1111/j.1399-6576.2007.01439.x
129. de Sousa AG, Junior CJF, Santos GPD, Laselva CR, Polessi J, Lisboa LF, et al. The impact of each action in the Surviving Sepsis Campaign measures on hospital mortality of patients with severe sepsis/septic shock. Einstein 2008; 6:323-7.
130. Subramanian S, Yilmaz M, Rehman A, Hubmayr RD, Afessa B, Gajic O. Liberal vs. conservative vasopressor use to maintain mean arterial blood pressure during resuscitation of septic shock: an observational study. Intensive Care Med 2008; 34:157-62. PMID:17924093; http://dx.doi.org/10.1007/s00134-007-0862-1.
131. Iscimen R, Cartin-Ceba R, Yilmaz M, Khan H, Hubmayr RD, Afessa B, Gajic O. Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. Crit Care Med 2008; 36:1518-22. PMID:18434908; http://dx.doi.org/10.1097/CCM.0b013e31816fc2c0.
132. Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, Ellis P, Guzman J, Marshall J, Parrillo JE, et al.; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009; 35:871-81. PMID:19066848; http://dx.doi.org/10.1007/s00134-008-1367-2.
133. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jiménez R, Barroso S, Ortiz-Leyba C. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 2006; 10:R111. PMID:16859504; http://dx.doi.org/10.1186/cc4995.
134. Calbo E, Alsina M, Rodríguez-Carballeira M, Lite J, Garau J. The impact of time on the systemic inflammatory response in pneumococcal pneumonia. Eur Respir J 2010; 35:614-8. PMID:19608588; http://dx.doi.org/10.1183/09031936.00052709.
135. Thiel SW, Asghar MF, Micek ST, Reichley RM, Doherty JA, Kollef MH. Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit Care Med 2009; 37:819-24. PMID:19237883; http://dx.doi.org/10.1097/CCM.0b013e318196206b
136. Nguyen HB, Corbett SW, Steele R, Banta J, Clark RT, Hayes SR, Edwards J, Cho TW, Wittlake WA. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med 2007; 35:1105-12. PMID:17334251; http://dx.doi.org/10.1097/01.CCM.0000259463.33848.3D
137. Sebat F, Musthafa AA, Johnson D, Kramer AA, Shoffner D, Eliason M, Henry K, Spurlock B. Effect of a rapid response system for patients in shock on time to treatment and mortality during 5 years. Crit Care Med 2007; 35:2568-75. PMID:17901831; http://dx.doi.org/10.1097/01.CCM.0000287593.54658.89.
138. Castellanos-Ortega A, Suberviola B, García-Astudillo LA, Holanda MS, Ortiz F, Llorca J, Delgado-Rodríguez M. Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: results of a three-year follow-up quasi-experimental study. Crit Care Med 2010; 38:1036-43. PMID:20154597; http://dx.doi.org/10.1097/CCM.0b013e3181d455b6.
139. Lefrant JY, Muller L, Raillard A, Jung B, Beaudroit L, Favier L, Masson B, Dingemans G, Thévenot F, Selcer D, et al.; Sepsi d'Oc study Group in the AzuRéa Group. Reduction of the severe sepsis or septic shock associated mortality by reinforcement of the recommendations bundle: a multicenter study. Ann Fr Anesth Reanim 2010; 29:621-8. PMID:20634026; http://dx.doi.org/10.1016/j.annfar.2010.04.007.
140. Cardoso T, Carneiro AH, Ribeiro O, Teixeira-Pinto A, Costa-Pereira A. Reducing mortality in severe sepsis with the implementation of a core 6-hour bundle: results from the Portuguese communityacquired sepsis study (SACiUCI study). Crit Care 2010; 14:R83. PMID:20459716; http://dx.doi.org/10.1186/cc9008.
141. Phua J, Koh Y, Du B, Tang YQ, Divatia JV, Tan CC, Gomersall CD, Faruq MO, Shrestha BR, Gia Binh N, et al.; MOSAICS Study Group. Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. BMJ 2011; 342:d3245. PMID:21669950; http://dx.doi.org/10.1136/bmj.d3245.
142. Patel GW, Roderman N, Gehring H, Saad J, Bartek W. Assessing the effect of the Surviving Sepsis Campaign treatment guidelines on clinical outcomes in a community hospital. Ann Pharmacother 2010; 44:1733-8. PMID:20978215; http://dx.doi.org/10.1345/aph.1P251.
143. Pestaña D, Espinosa E, Sangüesa-Molina JR, Ramos R, Pérez-Fernández E, Duque M, Martínez-Casanova E; REASEP Sepsis Study Group. Compliance with a sepsis bundle and its effect on intensive care unit mortality in surgical septic shock patients. J Trauma 2010; 69:1282-7. PMID:20134352; http://dx.doi.org/10.1097/TA.0b013e3181c4539f
144. Barochia AV, Cui X, Vitberg D, Suffredini AF, O'Grady NP, Banks SM, Minneci P, Kern SJ, Danner RL, Natanson C, et al. Bundled care for septic shock: an analysis of clinical trials. Crit Care Med 2010; 38:668-78. PMID:20029343; http://dx.doi.org/10.1097/CCM.0b013e3181cb0ddf
145. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584-602. PMID:9145732.
146. Ulldemolins M, Rello J. The relevance of drug volume of distribution in antibiotic dosing. Curr Pharm Biotechnol 2011; 12:1996-2001. PMID:21554218; http://dx.doi.org/10.2174/138920111798808365.
147. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 2011; 27:19-34. PMID:21144984; http://dx.doi.org/10.1016/j.ccc.2010.09.006.
148. del Mar Fernández de Gatta Garcia M, Revilla N, Calvo MV, Domínguez-Gil A, Sánchez Navarro A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33:279-85. PMID:17165021; http://dx.doi.org/10.1007/s00134-006-0470-5.
149. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56:4241-9. PMID:22615285; http://dx.doi.org/10.1128/AAC.06426-11.
150. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14:R126. PMID:20594297; http://dx.doi.org/10.1186/cc9091.
151. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14:R53. PMID:20370907; http://dx.doi.org/10.1186/cc8945.
152. Ocampos-Martinez E, Penaccini L, Scolletta S, Abdelhadii A, Devigili A, Cianferoni S, de Backer D, Jacobs F, Cotton F, Vincent JL, et al. Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients. Int J Antimicrob Agents 2012; 39:332-7. PMID:22333933; http://dx.doi.org/10.1016/j.ijantimicag.2011.12.008.
153. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149:443-8. PMID:6715900; http://dx.doi.org/10.1093/infdis/149.3.443.
154. Chelluri L, Jastremski MS. Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Crit Care Med 1987; 15:1143-5. PMID:3677767; http://dx.doi.org/10.1097/00003246-198712000-00015.
155. Pletz MW, Bloos F, Burkhardt O, Brunkhorst FM, Bode-Böger SM, Martens-Lobenhoffer J, Greer MW, Stass H, Welte T. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive Care Med 2010; 36:979-83. PMID:20336279; http://dx.doi.org/10.1007/s00134-010-1864-y
156. van Zanten ARH, Polderman KH, van Geijlswijk IM, van der Meer GYG, Schouten MA, Girbes ARJ. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008; 23:422-30. PMID:18725050; http://dx.doi.org/10.1016/j.jcrc.2007.11.011.
157. Wang J-T, Fang C-T, Chen Y-C, Chang S-C. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 2001; 47:246. PMID:11157921; http://dx.doi.org/10.1093/jac/47.2.246.
158. Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003; 51:971-5. PMID:12654757; http://dx.doi.org/10.1093/jac/dkg147.
159. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430-6. PMID:19433570; http://dx.doi.org/10.1128/AAC.01361-08.
160. Pea F, Viale P. Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? Crit Care 2009; 13:214. PMID:19519961; http://dx.doi.org/10.1186/cc7774.
161. Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med 2006; 100:2129-36. PMID:16730170; http://dx.doi.org/10.1016/j.rmed.2006.03.019.
162. Oparaoji EC, Siram S, Shoheiber O, Cornwell EE 3rd, Mezghebe HM. Appropriateness of a 4 mg/kg gentamicin or tobramycin loading dose in postoperative septic shock patients. J Clin Pharm Ther 1998; 23:185-90. PMID:9831969; http://dx.doi.org/10.1046/j.1365-2710.1998.00126.x
163. Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilatorassociated pneumonia. Crit Care 2012; 16:R218. PMID:23148736; http://dx.doi.org/10.1186/cc11862.
164. Calandra T, Glauser MP. Immunocompromised animal models for the study of antibiotic combinations. Am J Med 1986; 80(5C):45-52. PMID:3087166.
165. Lebel MH, McCracken GH Jr. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989; 83:161-7. PMID:2913547.
166. Lebel MH. Adverse outcome of bacterial meningitis due to delayed sterilization of cerebrospinal fluid. Antibiot Chemother (1971) 1992; 45:226-38. PMID:1610135.
167. Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 2004; 39:1314-20. PMID:15494908; http://dx.doi.org/10.1086/425009.
168. French GL. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 2006; 58:1107-17. PMID:17040922; http://dx.doi.org/10.1093/jac/dkl393.
169. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004; 38:864-70. PMID:14999632; http://dx.doi.org/10.1086/381972.
170. Lepper MH, Dowling HF. Treatment of pneumoccic meningitis with penicillin compared with penicillin plus aureomycin. Studies including observations on an apparent antagonism between penicillin and aureomycin. Arch Intern Med 1951; 88:489-94; http://dx.doi.org/10.1001/archinte.1951.03810100073006.
171. French GL, Ling TKW, Davies DP, Leung DTY. Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis. Br Med J (Clin Res Ed) 1985; 291:636-7. PMID:3928061; http://dx.doi.org/10.1136/bmj.291.6496.636.
172. Mathies AW Jr., Leedom JM, Ivler D, Wehrle PF, Portnoy B. Antibiotic antagonism in bacterial meningitis. Antimicrob Agents Chemother (Bethesda) 1967; 7:218-24. PMID:4970203.
173. Brown TH, Alford RH. Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism. South Med J 1985; 78:869-71. PMID:3892712; http://dx.doi.org/10.1097/00007611-198507000-00025.
174. Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults. Am J Med 1981; 71:199-209. PMID:7020416; http://dx.doi.org/10.1016/0002-9343(81)90106-6.
175. Scheld WM, Sande MA. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest 1983; 71:411-9. PMID:6826714; http://dx.doi.org/10.1172/JCI110785.
176. Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother 2001; 45:2018-22. PMID:11408217; http://dx.doi.org/10.1128/AAC.45.7.2018-2022.2001.
177. Denny AE, Peterson LR, Gerding DN, Hall WH. Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. Arch Intern Med 1979; 139:1026-31. PMID:475520; http://dx.doi.org/10.1001/archinte.1979.03630460058018.
178. Weinstein MP, Stratton CW, Ackley A, Hawley HB, Robinson PA, Fisher BD, Alcid DV, Stephens DS, Reller LB. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med 1985; 78:262-9. PMID:3881943; http://dx.doi.org/10.1016/0002-9343(85)90436-X
179. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345:1318-30. PMID:11794152; http://dx.doi.org/10.1056/NEJMra010082.
180. Weinstein MP, Stratton CW, Hawley HB, Ackley A, Reller LB. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987; 83:218-22. PMID:3303925; http://dx.doi.org/10.1016/0002-9343(87)90688-7.
181. Sculier JP, Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med 1984; 76:429-35. PMID:6702874; http://dx.doi.org/10.1016/0002-9343(84)90662-4.
182. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, Gioud-Paquet M, Dartois N, Ellis-Grosse EJ, Loh E; Tigecycline 305. cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a doubleblind phase 3 comparison study with vancomycinaztreonam. Antimicrob Agents Chemother 2005; 49:4658-66. PMID:16251309; http://dx.doi.org/10.1128/AAC.49.11.4658-4666.2005.
183. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Rose G. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9:251-61. PMID:16099700; http://dx.doi.org/10.1016/j.ijid.2005.05.003.
184. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E; 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5:88. PMID:16236177; http://dx.doi.org/10.1186/1471-2334-5-88.
185. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699-709. PMID:22467668; http://dx.doi.org/10.1093/cid/cis270.
186. Duke T, Poka H, Dale F, Michael A, Mgone J, Wal T. Chloramphenicol versus benzylpenicillin and gentamicin for the treatment of severe pneumonia in children in Papua New Guinea: a randomised trial. Lancet 2002; 359:474-80. PMID:11853793; http://dx.doi.org/10.1016/S0140-6736(02)07677-8.
187. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-31. PMID:2393284; http://dx.doi.org/10.1128/AAC.34.6.1227.
188. González C, Rubio M, Romero-Vivas J, González M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillinsusceptible organisms. Clin Infect Dis 1999; 29:1171-7. PMID:10524959; http://dx.doi.org/10.1086/313440.
189. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192-7. PMID:17984229; http://dx.doi.org/10.1128/AAC.00700-07.
190. Stryjewski ME, Szczech LA, Benjamin DK Jr., Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillinsusceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190-6. PMID:17173215; http://dx.doi.org/10.1086/510386.
191. Chan KE, Warren HS, Thadhani RI, Steele DJ, Hymes JL, Maddux FW, Hakim RM. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol 2012; 23:1551-9. PMID:22904350; http://dx.doi.org/10.1681/ASN.2012010050.
192. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12. PMID:11170948; http://dx.doi.org/10.1086/318486
193. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999; 18:199-202. PMID:10357054; http://dx.doi.org/10.1007/s100960050258.
194. Fagon J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, Falcone RE, Anholm JD, Paganin F, Fabian TC, et al.; Nosocomial Pneumonia Group. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000; 161:753-62. PMID:10712318; http://dx.doi.org/10.1164/ajrccm.161.3.9904115.
195. Fowler VG Jr., Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, et al.; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65. PMID:16914701; http://dx.doi.org/10.1056/NEJMoa053783.
196. Alder J. The use of daptomycin for Staphylococcus aureus infections in critical care medicine. Crit Care Clin 2008; 24:349-63, ix-x. PMID:18361950; http://dx.doi.org/10.1016/j.ccc.2007.12.010.
197. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10, quiz 11-2. PMID:9455502; http://dx.doi.org/10.1086/516284.
198. Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, Vance JW. Role for dual individualization with cefmenoxime. Am J Med 1984; 77(6A):43-50. PMID:6097124.
199. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31:345-51. PMID:18313273; http://dx.doi.org/10.1016/j.ijantimicag.2007.12.009.
200. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54:1111-6. PMID:20038614; http://dx.doi.org/10.1128/AAC.01183-09.
201. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67:608-16. PMID:495630; http://dx.doi.org/10.1016/0002-9343(79)90242-0.
202. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006; 28:122-7. PMID:16815689; http://dx.doi.org/10.1016/j.ijantimicag.2006.02.020.
203. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012; 16:R113. PMID:22742765; http://dx.doi.org/10.1186/cc11405.
204. Lodise TP Jr., Lomaestro BM, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extendedinfusion dosing strategy. Clin Infect Dis 2007; 44:357-63. PMID:17205441; http://dx.doi.org/10.1086/510590.
205. Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40:219-23. PMID:16449546; http://dx.doi.org/10.1345/aph.1G467.
206. Lorente L, Jiménez A, Palmero S, Jiménez JJ, Iribarren JL, Santana M, Martín MM, Mora ML. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007; 29:2433-9. PMID:18158083; http://dx.doi.org/10.1016/j.clinthera.2007.11.003.
207. Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML. Clinical cure of ventilatorassociated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009; 33:464-8. PMID:19150225; http://dx.doi.org/10.1016/j.ijantimicag.2008.10.025.
208. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56:236-44. PMID:23074313; http://dx.doi.org/10.1093/cid/cis856.
209. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5:581-9. PMID:16122681; http://dx.doi.org/10.1016/S1473-3099(05)70218-8.
210. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit Care Med 2009; 37:2071-8. PMID:19384201; http://dx.doi.org/10.1097/CCM.0b013e3181a0054d
211. Scaglione F, Mouton JW, Mattina R, Fraschini F. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother 2003; 47:2749-55. PMID:12936969; http://dx.doi.org/10.1128/AAC.47.9.2749-2755.2003.
212. Winterboer TM, Lecci KA, Olsen KM. Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients. J Pharm Pract 2010; 23:6-18. PMID:21507788; http://dx.doi.org/10.1177/0897190009356550.
213. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003; 52:668-74. PMID:12951354; http://dx.doi.org/10.1093/jac/dkg403.
214. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003; 17:529-43. PMID:14711075; http://dx.doi.org/10.1016/S0891-5520(03)00061-8.
215. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-81. PMID:8517694; http://dx.doi.org/10.1128/AAC.37.5.1073.
216. Zelenitsky SA, Ariano RE. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother 2010; 65:1725-32. PMID:20558470; http://dx.doi.org/10.1093/jac/dkq211.
217. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279:125-9. PMID:9440662; http://dx.doi.org/10.1001/jama.279.2.125.
218. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189:1590-7. PMID:15116294; http://dx.doi.org/10.1086/383320.
219. Jumbe NL, Lovie A, Liv M, et al. Pharmacodynamics of levofloxacin with different organisms: one size does not fit all (abstract 29). Program and Abstracts of the 40th Interscience Conference of Anti-Microbial Agents and Chemotherapy (Toronto)Washington, DC: American Society for Microbiology 2000.
220. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-81. PMID:21460309; http://dx.doi.org/10.1093/cid/cir124.
221. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925-42. PMID:15509186; http://dx.doi.org/10.2165/00003088-200443130-00005.
222. Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A; Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureusassociated septic shock. Int J Antimicrob Agents 2013; 41:255-60. PMID:23312606; http://dx.doi.org/10.1016/j.ijantimicag.2012.10.015.
223. De Jongh CA, Joshi JH, Thompson BW, Newman KA, Finley RS, Moody MR, Salvatore PC, Tenney JH, Drusano GL, Schimpff SC. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 1986; 80(5C):101-11. PMID:3521269.
224. Klastersky J, Zinner SH. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 1982; 4:294-301. PMID:7051232; http://dx.doi.org/10.1093/clinids/4.2.294.
225. Anderson ET, Young LS, Hewitt WL. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 1978; 24:45-54. PMID:412648; http://dx.doi.org/10.1159/000237759.
226. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986; 80(6B):126-37. PMID:3088998; http://dx.doi.org/10.1016/0002-9343(86)90490-0.
227. Comber KR, Basker MJ, Osborne CD, Sutherland R. Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrob Agents Chemother 1977; 11:956-64. PMID:406837; http://dx.doi.org/10.1128/AAC.11.6.956.
228. Archer G, Fekety FR Jr. Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin. J Infect Dis 1977; 136:327-35. PMID:903671; http://dx.doi.org/10.1093/infdis/136.3.327.
229. Yoshikawa TT, Shibata SA. In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa. Antimicrob Agents Chemother 1978; 13:997-9. PMID:98109; http://dx.doi.org/10.1128/AAC.13.6.997.
230. Kluge RM, Standiford HC, Tatem B, Young VM, Greene WH, Schimpff SC, Calia FM, Hornick RB. Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1974; 6:442-6. PMID:4157342; http://dx.doi.org/10.1128/AAC.6.4.442.
231. Gimeno C, Borja J, Navarro D, Valdés L, García-Barbal J, García-de-Lomas J. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections. Chemotherapy 1998; 44:94-8. PMID:9551238; http://dx.doi.org/10.1159/000007098.
232. Gradelski E, Kolek B, Bonner DP, Valera L, Minassian B, Fung-Tomc J. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int J Antimicrob Agents 2001; 17:103-7. PMID:11165113; http://dx.doi.org/10.1016/S0924-8579(00)00317-4.
233. Zembower TR, Noskin GA, Postelnick MJ, Nguyen C, Peterson LR. The utility of aminoglycosides in an era of emerging drug resistance. Int J Antimicrob Agents 1998; 10:95-105. PMID:9716286; http://dx.doi.org/10.1016/S0924-8579(98)00033-8.
234. Neu HC. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Drugs 1993; 45(Suppl 3):54-8. PMID:7689452; http://dx.doi.org/10.2165/00003495-199300453-00011.
235. Pohlman JK, Knapp CC, Ludwig MD, Washington JA. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli. Diagn Microbiol Infect Dis 1996; 26:29-33. PMID:8950526; http://dx.doi.org/10.1016/S0732-8893(96)00174-5.
236. Milatovic D, Wallrauch C. In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Eur J Clin Microbiol Infect Dis 1996; 15:688-93. PMID:8894583; http://dx.doi.org/10.1007/BF01691162.
237. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52:333-6. PMID:17967915; http://dx.doi.org/10.1128/AAC.00689-07.
238. Lin E, Stanek RJ, Mufson MA. Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 2003; 47:1151-3. PMID:12604560; http://dx.doi.org/10.1128/AAC.47.3.1151-1153.2003.
239. MacGowan AR, Bowker K, Bedford KA, Holt HA, Reeves DS. Synergy testing of macrolide combinations using the chequerboard technique. J Antimicrob Chemother 1993; 32:913-5. PMID:8144439; http://dx.doi.org/10.1093/jac/32.6.913.
240. Furuya R, Nakayama H, Kanayama A, Saika T, Iyoda T, Tatewaki M, Matsuzaki K, Kobayashi I, Tanaka M. In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006; 12:172-6. PMID:16944253; http://dx.doi.org/10.1007/s10156-006-0445-z
241. Maioli E, Debbia EA, Gualco L, Marchese A. In vitro interaction between mecillinam and piperacillintazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa. New Microbiol 2008; 31:37-46. PMID:18437840.
242. Allen NE, Epp JK. Mechanism of penicillinerythromycin synergy on antibiotic-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1978; 13:849-53. PMID:248271; http://dx.doi.org/10.1128/AAC.13.5.849.
243. Kumar A, Mensing J, Zelenitsky S, Ariano R, Parrillo JE. Effect of antibiotic sequence on blood bacterial counts in a rat model of E. coli peritonitis/septic shock. ICAAC Proceedings 2004:page 26; A-1296.
244. Darras-Joly C, Bédos JP, Sauve C, Moine P, Vallée E, Carbon C, Azoulay-Dupuis E. Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and-tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother 1996; 40:2147-51. PMID:8878597.
245. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979; 301:126-31. PMID:449951; http://dx.doi.org/10.1056/NEJM197907193010303.
246. De Jongh CA, Joshi JH, Newman KA, Moody MR, Wharton R, Standiford HC, Schimpff SC. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986; 80(5C):96-100. PMID:3717193.
247. Bouza E, Muñoz P. Monotherapy versus combination therapy for bacterial infections. Med Clin North Am 2000; 84:1357-89, v. PMID:11155848; http://dx.doi.org/10.1016/S0025-7125(05)70293-5.
248. Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents 2011; 37:491-503. PMID:21292449; http://dx.doi.org/10.1016/j.ijantimicag.2010.11.029.
249. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-27. PMID:15288826; http://dx.doi.org/10.1016/S1473-3099(04)01108-9.
250. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactamaminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668-79. PMID:14996699; http://dx.doi.org/10.1136/bmj.38028.520995.63.
251. Paul M, Soares-Weiser K, Leibovici L. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326:1111-8. PMID:12763980; http://dx.doi.org/10.1136/bmj.326.7399.1111.
252. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-42. PMID:11493124; http://dx.doi.org/10.1001/archinte.161.15.1837.
253. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, et al.; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440-4. PMID:15184200; http://dx.doi.org/10.1164/rccm.200311-1578OC
254. Rodríguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Solé-Violán J, Rello J; CAPUCI Study Group. Combination antibiotic therapy improves survival in patients with communityacquired pneumonia and shock. Crit Care Med 2007; 35:1493-8. PMID:17452932; http://dx.doi.org/10.1097/01.CCM.0000266755.75844.05.
255. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI, Rello J. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36:612-20. PMID:19953222; http://dx.doi.org/10.1007/s00134-009-1730-y
256. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90. PMID:1892329; http://dx.doi.org/10.7326/0003-4819-115-8-585.
257. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-6. PMID:2816969; http://dx.doi.org/10.1016/S0002-9343(89)80611-4.
258. Korvick JA, Bryan CS, Farber B, Beam TR Jr., Schenfeld L, Muder RR, Weinbaum D, Lumish R, Gerding DN, Wagener MM, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992; 36:2639-44. PMID:1482131; http://dx.doi.org/10.1128/AAC.36.12.2639.
259. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010; 38:1651-64. PMID:20562695; http://dx.doi.org/10.1097/CCM.0b013e3181e96b91.
260. Kumar A, Zarychanski R, Light B, Parrillo JE, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, et al.; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38:1773-85. PMID:20639750; http://dx.doi.org/10.1097/CCM.0b013e3181eb3ccd
261. Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, et al.; German Study Group Competence Network Sepsis (SepNet). Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 2012; 307:2390-9. PMID:22692171; http://dx.doi.org/10.1001/jama.2012.5833.
262. Al-Hasan MN, Wilson JW, Lahr BD, Thomsen KM, Eckel-Passow JE, Vetter EA, Tleyjeh IM, Baddour LM. Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gramnegative bacilli. Antimicrob Agents Chemother 2009; 53:1386-94. PMID:19164144; http://dx.doi.org/10.1128/AAC.01231-08.
263. Delannoy PY, Boussekey N, Devos P, Alfandari S, Turbelin C, Chiche A, Meybeck A, Georges H, Leroy O. Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias. Eur J Clin Microbiol Infect Dis 2012; 31:2293-9. PMID:22350387; http://dx.doi.org/10.1007/s10096-012-1568-z
264. Díaz-Martín A, Martínez-González ML, Ferrer R, Ortiz-Leyba C, Piacentini E, Lopez-Pueyo MJ, Martín-Loeches I, Levy MM, Artigas A, Garnacho-Montero J; for the Edusepsis Study Group. Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality. Crit Care 2012; 16:R223. PMID:23158399; http://dx.doi.org/10.1186/cc11869